Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:16 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
NCT04855136 · Celgene · PHASE1 · terminated · last registry update 2026-07-09 · Multiple myeloma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business objectives have changed” | Open Targets' class: business administrative | Registry record, Celgene |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFRSF17 in multiple myeloma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-22Phase 3 first posted: Alliance for Clinical Trials in Oncology, Daratumumab and Recombinant Human Hyaluronidase + Lenalidomide (NCT07887984)
- 2026-10-19Also stopped (suspended): National Cancer Institute (NCI), Iberdomide (NCT06179888)
- 2026-07-31Phase 3 first posted: Polish Myeloma Consortium, Teclistamab + Talquetamab (NCT07740486)
- 2026-07-27Phase 3 first posted: AbbVie, Etentamig + Pomalidomide (NCT07728188)
- 2026-06-26Phase 3 first posted: University of Heidelberg Medical Center, Teclistamab + Daratumumab (NCT07671287)
- 2026-06-16Phase 3 first posted: University of Leeds, Daratumumab + Lenalidomide (NCT07649525)
- 2026-04-24Also stopped (terminated): Pfizer, Elranatamab + Nirogacestat + Elranatamab + lenalidomide + dexamethasone (NCT05090566)
- 2026-04-08Phase 3 first posted: Janssen Research & Development, LLC, JNJ-79635322 + Teclistamab (NCT07518186)
- 2026-02-23Results posted on the registry: Pfizer, Elranatamab + Nirogacestat + Elranatamab + lenalidomide + dexamethasone (NCT05090566)
- 2026-01-12Results posted on the registry: Medical College of Wisconsin, Lenalidomide + bb2121 (NCT05032820)
- 2025-12-17Also stopped (terminated): Nanjing Legend Biotech Co., LCAR-B38M CAR-T Cell (NCT03758417)
- 2025-12-02Phase 3 first posted: Janssen Research & Development, LLC, JNJ-79635322 + Teclistamab (NCT07258511)
- 2025-08-22Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., QLS32015 + Pomalidomide (NCT07138209)
- 2025-07-29Also stopped (terminated): University of Washington, Vevoctadekin + Teclistamab (NCT06588660)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision